Using PET imaging to assess effects of SGLT2 inhibition on fatty acid uptake in brain and other tissues

In metabolic diseases such as type 2 diabetes (T2D), changes in fatty acid metabolism within individual tissues are often observed alongside development of insulin resistance. A deeper understanding of how fatty acid metabolism and insulin resistance are affected in tissues such as skeletal muscle, brain, small intestine, as well as subcutaneous (SAT) and visceral adipose tissue (VAT) is needed to better understand the pathophysiology of the disease and its progression, and potential pathways for treatment.

Research looking at the effects of sodium-glucose transporter 2 (SGLT2) inhibition on tissue fatty acid uptake (FAU) in individuals with T2D using [18F]FTHA positron emission tomography (PET) imaging has recently been published in Diabetes Care. The study showed that SGLT2 inhibition had differing effects on FAU in the skeletal muscle and brain, compared to the small intestine and adipose tissues. Some results from this study have previously been presented at the European Association for the Study of Diabetes (EASD) Annual Meeting.

The DAPACARD study was conducted as a collaboration between Turku PET Centre, AstraZeneca, and Antaros Medical.

Find the publication details below

Title: SGLT2 inhibitor Dapagliflozin increases skeletal muscle and brain fatty acid uptake in individuals with type 2 diabetes: a randomised double-blind placebo-controlled positron emission tomography study
Authors: Latva-Rasku A, Rebelos E, Tuisku J, Aarnio R, Bhowmik A, Keskinen H, Laurila S, Lahesmaa-Hatting M, Pekkarinen L, Isackson H, Kirjavainen AK, Koffert J, Heurling K, Nummenmaa L, Ferrannini E, Oldgren J, Oscarsson J, Nuutila P

Find the publication link here.

Share on Linkedin Share on Twitter